



Scholars Research Library

Der Pharma Chemica, 2015, 7(3):1-4  
(<http://derpharmachemica.com/archive.html>)



ISSN 0975-413X  
CODEN (USA): PCHHAX

## Synthesis and characterization of pyrazoline derivatives obtained from 4-bromo-naphthalen-1-ol

V. M. Sherkar\* and S. E. Bhandarkar<sup>1</sup>

Department of Chemistry, Government Vidarbha Institute of Science and Humanities,  
Amravati, (M.S.), India

### ABSTRACT

1-(4-bromo-1-hydroxynaphthalen-2-yl)-ethanone have been synthesized from 4-bromo-naphthalen-1-ol by refluxing it with glacial acetic acid in presence of fused  $ZnCl_2$  by modified Nenck's method. 1-(4-bromo-1-hydroxynaphthalen-2-yl)-3-aryl-prop-2-en-1-one were synthesized from 1-(4-bromo-1-hydroxy naphthalen-2-yl)-ethanone by condensing it with aromatic aldehydes. Then these newly synthesized 1-(4-bromo-1-hydroxy-naphthalen-2-yl)-3-aryl-prop-2-en-1-one were cyclized with nucleophiles like phenyl hydrazine / semicarbazide / thiosemi carbazide in DMF solvent and refluxed for 2 hours. The cooled reaction mixture was diluted with water the semisolid so obtained was triturated with ethanol to get a solid which was recrystallised from ethanol-acetic acid mixture to get pyrazoline derivatives. The synthesized compounds were characterized by elemental analysis, <sup>1</sup>H NMR, IR Spectroscopy.

**Key words:** Synthesis, characterization, IR Spectra, NMR Spectra, pyrazolines.

### INTRODUCTION

In recent scenario heterocycles play a major role in drug synthesis in that respect pyrazoline derivatives play a significant role among other heterocycles. From the literature survey, in recent years pyrazoline derivatives have attracted considerable interest because of their therapeutic and pharmacological properties. Pyrazolines are well known heterocyclic compound and important nitrogen-containing five-membered hetero-cyclic compounds and various methods have been worked out for their synthesis<sup>1-4</sup>. Various pyrazoline derivatives are important biological agents and a significant amount of research activity has been directed towards this class of compounds<sup>5-8</sup>. In particular, they show, antimycobacterial<sup>9</sup>, anti-inflammatory, analgesic<sup>10-12</sup> antidepressant activities<sup>13</sup>, bioactive heterocycles<sup>14-17</sup>, central nervous system stimulant and immuno suppressive,<sup>18</sup> antimicrobial<sup>19</sup> and antibacterial activities<sup>20</sup>.

Synthesis characterization and biological evaluation of pyrazoline derivatives becomes favorite field for many investigator their efforts are quite significant in literature. Hence, a series of novel pyrazoline derivatives from 4-bromo-naphthalen-1-ol has been synthesized.

## MATERIALS AND METHODS

The melting points ( $^{\circ}\text{C}$ ) were recorded by open capillary method and are uncorrected. IR spectra ( $\nu_{\text{max}}$  in  $\text{cm}^{-1}$ ) were recorded on a Shimadzu FTIR 8300 spectrophotometer using KBr pellets. The  $^1\text{H}$  NMR spectra were recorded on aDRX-300 (300 MHz) instrument using  $\text{CDCl}_3$  as solvent (chemical shift in  $\delta\text{ppm}$ ), and TMS as internal standard. Thin Layer Chromatography on silica gel-G, was used to check the purity of the compounds.

**Method and Discussion of result:****Synthesis of 1-(4-bromo-1-hydroxynaphthalen-2-yl)-ethanone (2)**

1-(4-bromo-1-hydroxynaphthalen-2-yl)-ethanone was prepared by refluxing 4-bromo-naphthalen-1-ol with glacial acetic acid in presence of fused  $\text{ZnCl}_2$ .

**Synthesis of 1-(4-bromo-1-hydroxy-naphthalen-2-yl)-3-aryl-prop-2-en-1-one (3-6)**

1-(4-bromo-1-hydroxynaphthalen-2-yl)-2-aryl-prop-2-en-1-one were synthesized from 1-(4-bromo-1-hydroxynaphthalen-2-yl)-ethanone by condensing it with aromatic aldehydes.

**Synthesis of pyrazoline derivatives (7-18)**

1-(4-bromo-1-hydroxynaphthalen-2-yl)-2-aryl-prop-2-en-1-one phenyl hydrazine / semicarbazide / thiosemi carbazide were added to DMF and refluxed for 2 Hours . The cooled reaction mixture was diluted with water the semisolid so obtained was triturated with ethanol to get a solid which was recrystallised from ethanol-acetic acid mixture to get pyrazoline derivatives.

Table 1. PHYSICAL DATA OF SYNTHESIZED COMPOUNDS

Sr.No.	Compound No	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Molecular formula	Melting Point $^{\circ}\text{C}$	% Yield	% Nitrogen		R.F. Value
								Found	Calculated	
1	3	-OCH <sub>3</sub>	-H	--		124 $^{\circ}\text{C}$	55%	--	--	--
2	4	-OCH <sub>3</sub>	-OCH <sub>3</sub>	--		120 $^{\circ}\text{C}$	53%	--	--	--
3	5	-H	-OH	--		140 $^{\circ}\text{C}$	57%	--	--	--
4	6	-OH	-H	--		144 $^{\circ}\text{C}$	59%	--	--	--
5	7	-OCH <sub>3</sub>	-H	C <sub>6</sub> H <sub>5</sub>	C <sub>26</sub> H <sub>21</sub> BrN <sub>2</sub> O <sub>2</sub>	205 $^{\circ}\text{C}$	43%	5.90	5.92	0.54
6	8	-OCH <sub>3</sub>	-OCH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub>	C <sub>27</sub> H <sub>23</sub> BrN <sub>2</sub> O <sub>3</sub>	203 $^{\circ}\text{C}$	45%	5.53	5.57	0.61
7	9	-H	-OH	C <sub>6</sub> H <sub>5</sub>	C <sub>25</sub> H <sub>19</sub> BrN <sub>2</sub> O <sub>2</sub>	217 $^{\circ}\text{C}$	42%	6.07	6.10	0.63
8	10	-OH	-H	C <sub>6</sub> H <sub>5</sub>	C <sub>25</sub> H <sub>19</sub> BrN <sub>2</sub> O <sub>2</sub>	225 $^{\circ}\text{C}$	38%	6.09	6.10	0.57
9	11	-OCH <sub>3</sub>	-H	-CONH <sub>2</sub>	C <sub>21</sub> H <sub>18</sub> BrN <sub>3</sub> O <sub>3</sub>	290 $^{\circ}\text{C}$	40%	9.51	9.55	0.58
10	12	-OCH <sub>3</sub>	-OCH <sub>3</sub>	-CONH <sub>2</sub>	C <sub>22</sub> H <sub>20</sub> BrN <sub>3</sub> O <sub>4</sub>	283 $^{\circ}\text{C}$	43%	8.93	8.94	0.62
11	13	-H	-OH	-CONH <sub>2</sub>	C <sub>20</sub> H <sub>16</sub> BrN <sub>3</sub> O <sub>3</sub>	278 $^{\circ}\text{C}$	41%	9.83	9.86	0.55
12	14	-OH	-H	-CONH <sub>2</sub>	C <sub>20</sub> H <sub>16</sub> BrN <sub>3</sub> O <sub>3</sub>	285 $^{\circ}\text{C}$	44%	9.85	9.86	0.54
13	15	-OCH <sub>3</sub>	-H	-CSNH <sub>2</sub>	C <sub>21</sub> H <sub>18</sub> BrN <sub>3</sub> O <sub>2</sub> S	185 $^{\circ}\text{C}$	42%	9.20	9.21	0.59
14	16	-OCH <sub>3</sub>	-OCH <sub>3</sub>	-CSNH <sub>2</sub>	C <sub>22</sub> H <sub>20</sub> BrN <sub>3</sub> O <sub>3</sub> S	179 $^{\circ}\text{C}$	43%	8.63	8.64	0.63
15	17	-H	-OH	-CSNH <sub>2</sub>	C <sub>20</sub> H <sub>16</sub> BrN <sub>3</sub> O <sub>2</sub> S	188 $^{\circ}\text{C}$	45%	9.48	9.50	0.62
16	18	-OH	-H	-CSNH <sub>2</sub>	C <sub>20</sub> H <sub>16</sub> BrN <sub>3</sub> O <sub>2</sub> S	197 $^{\circ}\text{C}$	41%	9.47	9.50	0.57

**Spectral interpretation of (7)**


**IR** ( $\nu_{\text{max}}$ ) ( $\text{cm}^{-1}$ ): 3337 (OH, str), 3217 (N-N pyrazoline), 1588 (C=N str), 3013 (CH str in Ar)

**NMR** ( $\delta$  ppm): 9.51 (s, 1H, OH), 3.077–3.154 (dd, 1H, H<sub>A</sub>), 3.618-3.718 (dd, 1H, H<sub>B</sub>), 5.297-5.252, (dd, 1H, H<sub>X</sub>), 8.17- 8.73 (m, 14Ar-H), 3.75 (s, 3H, OCH<sub>3</sub>).

**Spectral interpretation of (12)**

**IR** ( $\nu_{\text{max}}$ ) ( $\text{cm}^{-1}$ ): 3333 (OH str), 3221 (N-N pyrazoline), 1583 (C=N str), 1663 (NH bend)

**NMR** ( $\delta$  ppm): 3.087–3.162 (dd, 1H, H<sub>A</sub>), 3.626-3.726 (dd, 1H, H<sub>B</sub>), 5.205-5.260, (dd, 1H, H<sub>X</sub>) 8.13- 8.78 (m, 9 Ar-H), 10.08 (s, 1H, OH), 8.98 (s, 1H, OH), 6.73 (s, 2H, NH<sub>2</sub>).

**Acknowledgment**

The Author are thankful to Dr.A.R.Raut, Head , Department of Chemistry and Director, G.V.I.S.H. Amravati for providing necessary lab facility.

**REFERENCES**

- [1] *Pyrazoles, Pyrazolines, Pyrazolidines, Indazoles and Condensed Rings, in the Chemistry of Heterocyclic Compounds*, edited by A. Weissberger (Interscience Publishers, New York), **1967**, Vol 22,180.
- [2] Elguero J, in *Comprehensive Heterocyclic Chemistry II*, edited by A. R. Katritzky , C. W. Rees E. F. Scriven, (Pergamon Press, Oxford), **1996**, Vol 3,1.
- [3] A. Levai, *Khim Geterotsikl Soedin*, **1997**, 747.
- [4] A. Levai, *J Heterocycl Chem* **2002**,39, 1.
- [5] G. Turan-Zitouni, A. Ozdemir K. Guven , *Arch Pharm*, **2005**,338, 96.
- [6] G. Turan-Zitouni, A. Ozdemir ,Z.A. Kaplancikh ,P. Chevallet Y. Tunah , *Phosphorus Sulfur Silicon*, **2005**,180, 2717.
- [7] Z.A.Kaplancikh , G. Turan-Zitouni, A. Ozdemir ,G. Revival K. Guven, *Phosphorus Sulfur Silicon*, **2007**,182, 749.
- [8] A. Ozdemir , G. Turan-Zitouni, Z.A.Kaplancikh, G. Revival K. Guven , *Eur J Med Chem*, **2007**,42, 403.
- [9] M. Shaharyar , A.A.Siddiqui, M.A. Ali , D. Sriram P. Yogeewari , *Bioorg Med Chem Lett*, **2006**,16, 3947.
- [10] R.A.Nugent , M.Murphy, S.T.Schachter , C.J.Dunn , R.J.Smith , N.D.Staite T.L.A.Galine , *J Med Chem*,

1993, 36, 134.

[11] F.Manna , F.Chementi ,A. Bolasco, M.L.Cenicola, C.Parnillo, F.Rossi E. Marno , *Eur J Med Chem*, **1992**,27, 633.

[12] A.Bilgina , E.Palaska R.Sunal, *Arzneim Forsch, Drug Res*, **1993**,43, 1041.

[13] A.Bilgina , E.Palaska , R.Sunal B.Gumusel, *Pharmazie*, **1994**,49, 67.

[14] P.V.Badadhe , N.M.Chavan , D.R.Nagargoage C.H. Gill , *Indian J Heterocycl Chem*, **2009**, 19,175.

[15] D.S.Ghotekar,P.G. Mandhane, R.S.Joshi , S.S.Bhagat C.H.Gill , *Indian J Heterocycl Chem*, **2009**,19, 101.

[16] G.R.Jadhav , M.U.Shaikh , R.P.Kale , M.Shiradkar C.H. Gill , *Eur J Med Chem*, **2012**,44(9), 2930.

[17] S.N.Shelke , N.R.Dalvi , S.B.Kale , M.S.More , B.K.Karale C.H.Gill , *Indian J Chem*, **2013**,46, 1174.

[18] I.G.Lombardino I.G.I. Otterness , *Med Chem*, **1981**,24, 830.

[19] K.Ramalingham , G.X.Thyvekikakath , K.D.Berlin , R.W.Chestnut , R.A.Brown , N.N. Durham A.E.Ealick D.Van der Helm , *J Med Chem*, **1977**,20, 847.

[20] D.Azarifar S.Maseud , *Molecules*, **2002**,7, 85.